{"title":"补充富含亚精胺的水稻胚芽提取物对健康衰老和自噬生物标志物的影响——概念验证试点研究。","authors":"Gene Bruno, Michael La Monica, Tim N Ziegenfuss","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although epidemiological and preclinical research suggests that the polyamine spermidine improves the efficiency of autophagy, human clinical research demonstrating a specific dose of any source of spermidine capable of increasing biomarkers of autophagy is lacking.</p><p><strong>Primary study objective: </strong>The study aimed to examine the effects of spermidine from Miricell™ rice germ extract (Nutraland USA) on biomarkers/indices of autophagy, neuroprotection, and cardiometabolic health, as well as safety and adverse events.</p><p><strong>Methods/design: </strong>This 56-day study was conducted as a single-blinded, interventional, parallel-group, pilot trial. Vitals, diet records, and protocol compliance were recorded at weeks 0 and 8. Blood draws for cardiometabolic markers and adverse event monitoring took place at screening and weeks 0 and 8.</p><p><strong>Setting: </strong>Conducted at a clinical research laboratory in Ohio.</p><p><strong>Participants: </strong>Twelve (N=12) healthy men and women (age: 54.5 ± 7.9 years).</p><p><strong>Intervention: </strong>Random assignment to 1.5 mg or 3.3 mg of spermidine daily from Miricell™ rice germ extract (Nutraland USA).</p><p><strong>Primary outcome measures: </strong>Biomarkers of autophagy [Beclin-1 and Unc-51-like kinase 1(ULK1)], and biomarkers/indices of neuroprotection, including brain-derived neurotrophic factor (BDNF), homocysteine, and cardiometabolic health (high sensitivity C-reactive protein (hs-CRP), lipid panel).</p><p><strong>Results: </strong>Compared to baseline, only the 3.3 mg dose of spermidine from Miricell® increased Beclin-1 by 7.3%, ULK-1 by 13.4%, and BDNF by 12.1%. Compared to baseline, the same dose resulted in a 20.8% decrease in hs-CRP, a 20.1% decrease in VLDL, and a 26.9% decrease in triglycerides. Secondary outcomes, including clinical chemistry panel, CBC, vital signs, and adverse events, reflect a good safety profile for the use of 3.3 mg/day of spermidine from Miricell®.</p><p><strong>Conclusion: </strong>This pilot study found that 3.3 mg/day of spermidine from Miricell® rice germ extract tends to improve biomarkers of autophagy, neuroprotection, and cardiometabolic health. Appropriate follow-up studies are warranted to confirm these findings.</p><p><strong>Keywords: </strong>spermidine, autophagy, beclin-1, ULK1, rice germ extract, neuroprotection, BDNF, homocysteine, cardiometabolic, CRP, C-reactive protein, VLDL, triglycerides, aging.</p>","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Spermidine-Rich Rice Germ Extract Supplement on Biomarkers of Healthy Aging and Autophagy-Proof-of-Concept Pilot Study.\",\"authors\":\"Gene Bruno, Michael La Monica, Tim N Ziegenfuss\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although epidemiological and preclinical research suggests that the polyamine spermidine improves the efficiency of autophagy, human clinical research demonstrating a specific dose of any source of spermidine capable of increasing biomarkers of autophagy is lacking.</p><p><strong>Primary study objective: </strong>The study aimed to examine the effects of spermidine from Miricell™ rice germ extract (Nutraland USA) on biomarkers/indices of autophagy, neuroprotection, and cardiometabolic health, as well as safety and adverse events.</p><p><strong>Methods/design: </strong>This 56-day study was conducted as a single-blinded, interventional, parallel-group, pilot trial. Vitals, diet records, and protocol compliance were recorded at weeks 0 and 8. Blood draws for cardiometabolic markers and adverse event monitoring took place at screening and weeks 0 and 8.</p><p><strong>Setting: </strong>Conducted at a clinical research laboratory in Ohio.</p><p><strong>Participants: </strong>Twelve (N=12) healthy men and women (age: 54.5 ± 7.9 years).</p><p><strong>Intervention: </strong>Random assignment to 1.5 mg or 3.3 mg of spermidine daily from Miricell™ rice germ extract (Nutraland USA).</p><p><strong>Primary outcome measures: </strong>Biomarkers of autophagy [Beclin-1 and Unc-51-like kinase 1(ULK1)], and biomarkers/indices of neuroprotection, including brain-derived neurotrophic factor (BDNF), homocysteine, and cardiometabolic health (high sensitivity C-reactive protein (hs-CRP), lipid panel).</p><p><strong>Results: </strong>Compared to baseline, only the 3.3 mg dose of spermidine from Miricell® increased Beclin-1 by 7.3%, ULK-1 by 13.4%, and BDNF by 12.1%. Compared to baseline, the same dose resulted in a 20.8% decrease in hs-CRP, a 20.1% decrease in VLDL, and a 26.9% decrease in triglycerides. Secondary outcomes, including clinical chemistry panel, CBC, vital signs, and adverse events, reflect a good safety profile for the use of 3.3 mg/day of spermidine from Miricell®.</p><p><strong>Conclusion: </strong>This pilot study found that 3.3 mg/day of spermidine from Miricell® rice germ extract tends to improve biomarkers of autophagy, neuroprotection, and cardiometabolic health. Appropriate follow-up studies are warranted to confirm these findings.</p><p><strong>Keywords: </strong>spermidine, autophagy, beclin-1, ULK1, rice germ extract, neuroprotection, BDNF, homocysteine, cardiometabolic, CRP, C-reactive protein, VLDL, triglycerides, aging.</p>\",\"PeriodicalId\":7571,\"journal\":{\"name\":\"Alternative therapies in health and medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alternative therapies in health and medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Effects of Spermidine-Rich Rice Germ Extract Supplement on Biomarkers of Healthy Aging and Autophagy-Proof-of-Concept Pilot Study.
Background: Although epidemiological and preclinical research suggests that the polyamine spermidine improves the efficiency of autophagy, human clinical research demonstrating a specific dose of any source of spermidine capable of increasing biomarkers of autophagy is lacking.
Primary study objective: The study aimed to examine the effects of spermidine from Miricell™ rice germ extract (Nutraland USA) on biomarkers/indices of autophagy, neuroprotection, and cardiometabolic health, as well as safety and adverse events.
Methods/design: This 56-day study was conducted as a single-blinded, interventional, parallel-group, pilot trial. Vitals, diet records, and protocol compliance were recorded at weeks 0 and 8. Blood draws for cardiometabolic markers and adverse event monitoring took place at screening and weeks 0 and 8.
Setting: Conducted at a clinical research laboratory in Ohio.
Participants: Twelve (N=12) healthy men and women (age: 54.5 ± 7.9 years).
Intervention: Random assignment to 1.5 mg or 3.3 mg of spermidine daily from Miricell™ rice germ extract (Nutraland USA).
Primary outcome measures: Biomarkers of autophagy [Beclin-1 and Unc-51-like kinase 1(ULK1)], and biomarkers/indices of neuroprotection, including brain-derived neurotrophic factor (BDNF), homocysteine, and cardiometabolic health (high sensitivity C-reactive protein (hs-CRP), lipid panel).
Results: Compared to baseline, only the 3.3 mg dose of spermidine from Miricell® increased Beclin-1 by 7.3%, ULK-1 by 13.4%, and BDNF by 12.1%. Compared to baseline, the same dose resulted in a 20.8% decrease in hs-CRP, a 20.1% decrease in VLDL, and a 26.9% decrease in triglycerides. Secondary outcomes, including clinical chemistry panel, CBC, vital signs, and adverse events, reflect a good safety profile for the use of 3.3 mg/day of spermidine from Miricell®.
Conclusion: This pilot study found that 3.3 mg/day of spermidine from Miricell® rice germ extract tends to improve biomarkers of autophagy, neuroprotection, and cardiometabolic health. Appropriate follow-up studies are warranted to confirm these findings.
期刊介绍:
Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field.
Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.